Drug Guidance

Ustekinumab biosimilar for treating inflammatory conditions

-

Feature Articles

Zolbetuximab for untreated HER2-negative, claudin-18.2-positive, unresectable advanced gastric or gastroesophageal junction adenocarcinoma

-

Drug Guidance

Capivasertib in combination with fulvestrant for HR-positive, HER2-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration

-

Drug Guidance

Asciminib for Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase after two or more tyrosine kinase inhibitors

-

Drug guidance

Ribociclib for the adjuvant treatment of HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence

-

Drug Guidance

Inavolisib in combination with palbociclib and fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer

-

Drug Guidance

Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

Withdrawn

Trastuzumab deruxtecan for unresectable or metastatic non-small-cell lung cancer whose tumours have activating HER2 (ERBB2) mutations and who have received a prior systemic therapy

-

Drug Guidance

Trastuzumab deruxtecan for unresectable or metastatic HER2-positive solid tumours after at least one prior line of systemic therapy

-

Drug Guidance

Nivolumab in combination with ipilimumab and chemotherapy for untreated metastatic or recurrent non-small-cell lung cancer in patients whose tumours express PD-L1 with a tumour proportion score <1% with no EGFR or ALK genomic tumour mutations

-

Drug Guidance